NRP1 and neoplasm: Besides, tolerogenic tumor-associated DCs express IDO (indoleamine 2,3 dioxygenase), PD-L1, or semaphorin-4a (the ligand for Nrp1) to resist the inflammation-induced reprogramming of Tregs in vivo.